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he Value of Selectivity*
ntonio Colombo, MD, FACC,†
oran Stankovic, MD, FACC‡
ilan, Italy; and Belgrade, Serbia
or a drug to be defined a medication and not a placebo it is
mportant that the medication proves more effective in pre-
enting or treating a pathologic condition. This goal is always
chieved by paying two prices: the higher cost of the drug
ompared to the placebo and the higher risk of side effects. The
alue of selectivity and the identification of the specific
atients who may benefit the most from the administration
f a drug is very important.
It should be borne in mind that patients undergoing
ercutaneous coronary intervention (PCI) in the midst of an
cute coronary event or with multiple complex lesions may
equire a different level of anticoagulation and platelet
nhibition than low-risk patients undergoing elective PCI
or stable angina pectoris with simple lesions. Similarly,
eneralizing antithrombotic regimen safety data to a wide
pectrum of catheter-based therapeutic devices should be
voided.
See page 715
These are the main reasons why we consider the suba-
alysis of the Enhanced Suppression of the Platelet IIb/IIIa
eceptor with Integrilin Therapy (ESPRIT) trial by Puma
t al. (1) reported in this issue of the Journal to be an
mportant useful contribution toward improving the care of
ur patients undergoing PCI.
Use of IIb/IIIa inhibitors during PCI has demonstrated
n absolute reduction of 1.5% to 6.5% in the 30-day risk of
eath, myocardial infarction, or repeat urgent revasculariza-
ion, with some variability in treatment effect among the
gents tested (abciximab, eptifibatide, and tirofiban) (2).
The ESPRIT trial is the first step in evaluating the
linical value in PCI of another IIb/IIIa inhibitor in
ddition to abciximab with an already proven efficacy (3–6).
his trial demonstrated that eptifibatide, when used with
ppropriate dosing to guarantee over 80% effective plate-
et inhibition, can significantly lower complications after
CI (7).
Puma et al. (1) used a simple and straightforward classi-
cation to define a high-risk patient: age 75 years,
resence of diabetes mellitus (including diet-controlled
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †EMO Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy;i
nd the ‡Institute for Cardiovascular Disease, Clinical Center of Serbia, Belgrade,
erbia.iabetes), elevated creatine kinase (CK)-MB or troponin at
dmission, ST-segment elevation myocardial infarction
STEMI) within 7 days of admission, and unstable angina
ithin 48 h from admission. It is necessary to point out that
he ESPRIT trial enrolled only patients undergoing elective
tenting. This subanalysis categorizes a high-risk population
rom a larger group of patients apparently at low risk.
The ESPRIT trial enrolled 2,064 patients and 1,018 of
hem had at least one adverse baseline characteristic as
efined by Puma et al. (1).
Death and myocardial infarction defined as CK-MB
levation more than three times the normal value at 30 days
nd at 12 months were the end points evaluated. This end
oint is different from the primary composite endpoint of
he ESPRIT trial, which included death, myocardial infarc-
ion, urgent target vessel revascularization, and thrombotic
ailout glycoprotein IIb/IIIa inhibitor therapy within 48 h
fter randomization. In addition, the investigators of the
SPRIT trial separately evaluated the occurrence of large
ersus small myocardial infarctions.
A concern arises with the decision to use the cut-off value
f three times elevation of CK-MB rather that eight times
s suggested by others (8) and not having available for the
eader the incidence of non–Q-wave myocardial infarction
ccording to this last definition.
The important findings of this study are that the inci-
ence of the prespecified end point at 30 days in the
igh-risk group decreased from 12.38% in the placebo
roup to 6.19% in the eptifibatide group (p  0.001). The
ncidence of corresponding events in the low-risk groups
ere minimally different, 8.03% and 6.51%, respectively,
nd without statistical significance. A clear and significant
dvantage in the high-risk group persisted at 12 months:
5.89% in the placebo group versus 7.99% in the eptifibatide
roup (p 0.001). When we calculate that 14 patients need
o be treated to prevent one adverse event at one year we
nd a robust recommendation.
The authors report that bleeding complications were
igher in the eptifibatide group, but this difference was not
tatistically significant. However it would have been inter-
sting to see the incidence of severe and minor bleeding
omplications in the high- and low-risk groups. In the
SPRIT trial there was a trend toward increased rates of
leeding with eptifibatide (9). Another particular group of
atients that always generates concern regarding possible
leeding complications are the ones older than 75 years, and
pecific information in this subgroup would have been of
nterest.
It is important to consider that the characteristics used by
uma et al. (1) to define high-risk patients were only clinical
ithout any specific evaluation of the complexity of the
esions.
Currently, PCI with drug-eluting stents is performed on
omplex lesions in addition to complex patients. It will be of
nterest to see how some lesion and procedural characteristics,
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Editorial Comment February 21, 2006:719–20uch as bifurcations, use of multiple long stents, or overlapping
tents may further help to better define high-risk subgroups
here enhanced platelet inhibition may be of advantage. A
reviously reported subanalysis of the ESPRIT trial showed
hat patients treated with eptifibatide had trends toward
ewer angiographic complications: 10% versus 12% (p 
.13). In addition patients who sustained angiographic
omplications and received eptifibatide had fewer subse-
uent CK-MB elevations (43% vs. 50%; p  0.31) (10).
hese types of angiographic complications may become
ore frequent with use of long stents to treat long lesions
nd diffuse disease. It is therefore reasonable to assume that
atients with complex lesions may further benefit from an
ntense antiplatelelet therapy.
In the ESPRIT trial, 97% of the patients received
lopidogrel with a 300-mg loading dose when needed.
espite eptifibatide treatment, high-risk patients had an
ncidence of death and myocardial infarction of 6.19% at 30
ays, which means that there is room for further improve-
ent. There are recent data regarding the benefit of a loading
ose of 600 mg of clopidogrel and statin pretreatment (11–14).
n addition new antithrombotic agents such as bivalirudin are
outinely used during PCI in some centers (15).
New therapies and recommendations become continu-
usly available to the clinician. It is therefore important to
emember the concept highlighted at the beginning: An
stute clinical scientist needs to better tailor potent and
xpensive therapies to the patient who will benefit the most.
oday this decision is performed by obtaining a complete
istory and evaluating the clinical conditions and coronary
natomy of the patient; it may be possible that in the future
enetic mapping may further refine this task.
eprint requests and correspondence: Dr. Antonio Colombo,
MO Centro Cuore Columbus, Via M. Buonarroti 48, 20145
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